Purpose: We previously found that an epithelial-to-mesenchymal transition (EMT)-based gene expression signature was highly correlated with the first principal component (PC1) of 326 colorectal cancer tumors and was prognostic. This study was designed to improve these signatures for better prediction of metastasis and outcome.
Introduction
The heterogeneity of colorectal cancer makes it difficult to determine which patients will benefit from adjuvant therapy and which patients do not require further therapy beyond surgical resection. Thus, there is an urgent need for objective molecular classification to stratify adjuvant therapy for colorectal cancer patients (1) (2) (3) . One major challenge is the identification of factors to evaluate the potential of distant metastasis that has contributed to most of colorectal cancer mortality. Metastasis is a complex series of steps, including the tumor cell invasion and dissemination, survival in circulation, organ-specific targeting, tumor dormancy, and reactivation for colonization at distant sites (4, 5) . The epithelial-tomesenchymal transition (EMT) has been intensely studied in various types of cancers (especially breast cancer) as a major mechanism promoting invasion and metastasis (5, 6) . EMT has also been reported as one of the mechanisms contributing to the resistance to cetuximab (anti-EGFR) therapy (7) . However, the biology for most steps of metastasis, especially after the early steps of invasion and dissemination, is still poorly understood (4, 5) . This has greatly restricted our ability to understand and predict metastatic potential in cancer patients and has led to generalized "one size fits all" approaches to the administration of adjuvant therapy.
We have previously shown that EMT gene expression signatures can predict poor outcome in colorectal cancer and breast cancer (3, 8, 9) . In an unsupervised analysis, our past work yielded a list of top-ranked genes bearing positive and negative correlation with the first principal component (PC1) of colorectal cancer expression dataset of 326 tumors (8) . Of many signatures tested, our "EMT signature", derived from a gene expression analysis of 93 lung cancer cell lines sorted (based on their expression of CDH1 or VIM) into epithelial or mesenchymal groups, showed a very strong correlation (Pearson R ¼ 0.92; P < 10 À135 ) with PC1. This PC1 and EMT association was confirmed in 38 colorectal cancer cell lines, and was also verified by assessment of other known EMT-related genes and miRNAs in colorectal cancer tumors (8) . Both PC1 and EMT signatures were found to predict recurrence (indicating metastasis; ref. 8) .
To further assess the respective prognostic values of the PC1 and EMT signatures, we recently evaluated the outcomes on a new set of 468 colorectal cancer tumors (Moffitt468). The improvement in prognostic power noted in a bivariable survival model, when the two signatures were put in competition with each other, prompted us to generate a composite signature (DPC1.EMT) by subtracting EMT from PC1. Consequently, DPC1.EMT emerges as a new prognostic score for colorectal cancer prognosis, which could predominantly capture the non-EMT biologic features to optimize prediction of metastasis and outcome.
Materials and Methods

Tumor samples
The cohort of 468 colorectal adenocarcinoma patients (Moffitt468 dataset) from 468 distinct patients, including 367 primary lesions (306 stage I-III and 61 stage IV) and 101 metastatic lesions (49 from stage IV patients), with global gene expression analysis data from the surgical specimen, microsatellite instability (MSI) status, and targeted gene sequencing (Supplementary Table S1 ), with samples obtained between October 2006 and September 2010, was used to develop the "difference score" DPC1.EMT. Metastatic samples were included only for patients for whom primary samples were not sequenced. DPC1.EMT was then validated on 1,544 independent primary and metastatic tumors. In all cases, tissue and clinical data were collected on patients under institutional review board approval as part of the Total Cancer Care (TCC) project (10) .
We assessed/selected five additional large, independent colorectal cancer datasets from public resources (GEO and ArrayExpress) for cohorts of colorectal cancer patients with more than 100 samples, gene expression profile as well as relevant clinical information (including stage and follow-up) to be used to validate prognostic value and to determine biological significance. These include PETACC3, ALMAC, LNCC, GEO41258, and GSE14333 (refs. 3, 11-14; Supplementary Table S2) . Notably, PETACC3 was selected because it is one of the largest gene expression profile set derived from stage II & III patients recruited in a single clinical trial, while other datasets were retrospective collections of patients. Moreover, the TCGA adenocarcionoma dataset (15) was also used for biologic interpretation.
DPC1.EMT score computation
Probe intensities were preprocessed using RMA. PC1 and EMT scores were calculated as previously described (8) . Briefly, for each of the datasets, a score was computed for each of the 4 signatures (EMT.UP.score, EMT.DOWN.score, PC1.UP.score and PC1. DOWN.score) as the arithmetic mean of all probesets corresponding to gene symbols present in the corresponding gene signature (Supplementary Table S3 ). EMT and PC1 scores were then obtained as follows:
EMT.score ¼ EMT.UP.score À EMT.DOWN.score. PC1.score ¼ PC1.UP.score À PC1.DOWN.score.
The DPC1.EMT score was computed as follows: DPC1.EMT score ¼ PC1.score À EMT.score.
Scores were standardized by subtracting the score median and dividing by the score IQR. For Moffitt 468 dataset, the score median (interquartile range) for the PC1, EMT, and DPC1.EMT scores are À0.29 (À0.42 to À0.18), À0.38 (À0.55 to 0.21), and À0.09 (À0.17 to 0.01), respectively.
Correlation analysis
Pearson product moment correlation coefficient was used to quantify the association between the scores, MSI status, and mutation status for various driver genes.
GO Process analysis
Pathway analysis of the nonoverlapped genes of PC1 (i.e., PC1 genelist minus PC1 and EMT overlapped gene list) by GO Process was performed using the MetaCore package. A P value cut-off of 0.05 unadjusted for multiplicity resulted in 35 significant dysregulated pathways.
Hierarchical cluster analysis
We performed hierarchical clustering of five datasets (PETACC3, ALMAC, LNCC, GEO41258, and GSE14333) to visualize how the genes included in the signature grouped across different cohorts and platforms. To do that across all the datasets, we had to collapse the expression at the gene level selecting the probset which showed the higher variability (measured by median absolute deviation). We also tested the association of each gene to overall survival (OS) and relapse-free survival (RFS) using a meta-analytical approach.
Weight contributions of individual signature genes
To characterize the three signatures (PC1, EMT, and DPC1. EMT), we estimated the average contribution of each gene to each of the signatures across the five datasets. Within each dataset, we first calculated a weight for each probe set in the PC1 and EMT signatures, respectively. The weight was defined as 1/P þ for probe sets with positive weight and À1/P À for probe sets with negative weight in the signature. Here, P þ and P À are the total number of probe sets with positive and negative
Translational Relevance
The heterogeneity of colorectal cancer results in an urgent need for objective molecular classification to stratify adjuvant therapy for colorectal cancer patients. One major challenge is to evaluate the potential of distant metastasis, which has contributed the most to colorectal cancer mortality. The new prognostic signature score developed and validated in this study was shown to be a "best of assessed" prognostic signature score demonstrating a refined capacity to predict metastasis and outcomes in colorectal cancer, with a non-EMT propensity including epithelial cancer stem cell-related properties. The finding has clinical utility in determining which patients will have metastases and which will not, in otherwise good and poor prognosis lesions (all stages, microsatellite instability, and within mutational subgroups). The signature may have the potential to identify which patients may or may not benefit from adjuvant chemotherapy-a problem for which there is no current solution.
weight, respectively. The contribution of a probe set to a signature in a given dataset was then defined as the product between the weight of the probe set and its average expression level across the dataset. By summing contributions for all probe sets corresponding to a given gene, we estimated gene-wise contributions to each signature. The contributions to the DPC1. EMT signature were obtained as the difference between the contributions to the PC1 and the EMT signatures. The final estimates of gene contributions to the three signatures were obtained as weighted averages of the gene contributions across all five datasets to obtain final estimates of the gene contributions to the three signatures. The weight for a data set in this sum was inversely proportional to the Euclidean norm of the vector of gene contributions to the PC1 and EMT signatures in the dataset. A linear contrast was used to test for a trend in gene expression score with increasing stage of primary disease to distant metastasis, using PROC GLM (SAS, version 9.2).
Association of gene expression with DPC1.EMT score We tested the association of gene expression with the DPC1. EMT score within each of the five datasets plus TCGA colorectal cancer dataset (15) by a linear regression model with the score as the explanatory variable using the "limma" R package (version 3.16.3; ref. 16 ), adjusting SEs estimates by an empirical Bayes approach. P values were combined across datasets using Fisher method (MADAM R package version 1.2.2). A Bonferroni correction was applied to control for false positive results introduced by multiple testing. Genes showing an adjusted P value <0.00001 were split in two groups: those positively (N ¼ 2,983) and those negatively (N ¼ 2,221) correlated with the DPC1.EMT score.
Gene set enrichment analysis (GSEA) was performed to interpret the list of genes found to be correlating with DPC1.EMT score. The functional tool DAVID (http://david.abcc.ncifcrf.gov/) was employed to identify annotation terms enriched within each of the groups. We also performed GSEA using gene sets obtained from the MSig database (DB; ref. 12; MSigDB) which includes C2 (curated gene sets -Chemical and Genetic Perturbations, Biocarta and KEGG), C3 (transcription factors), C5 (GO biological process terms), C6 (oncogenic signature), and C7 (immunologic signatures). The analysis was done using the "Romer" algorithm (similar to GSEA; ref. 12) and the same linear model used to identify genes correlating with DPC1.EMT score. The P values obtained across the datasets were merged using Fisher method.
Survival analysis
We performed the Kaplan-Meier survival analysis on the Moffitt468 dataset and used Cox proportional hazards regression models in the R package "survival" (version 2.37-7) to assess association of tumor scores with OS, RFS, and/or survival after relapse (SAR) on the other five datasets.
Univariate analysis (OS and RFS) of 10 other known prognostic signatures
We selected a set of gene signatures known to be prognostic in colorectal cancer and could be computed from gene expression profiles. We computed the scores from 10 signatures (RAS Merck (17) , RAS Astrazeneca (18), OncotypeDX colon (19) , Veridex (20) , MD Anderson (21), Decorin (9), MED12 (22) , BRAF score (23), and ALM (12) on the five datasets as described in the original studies.
Results
DPC1.EMT outperformed both PC1 and EMT in predicting metastasis and survival
Our analysis of the Moffitt468 dataset showed that PC1 and EMT were highly correlated (Fig. 1A , top, Pearson R ¼ 0.90, P < 0.0001). The EMT score can be used to separate tumors with epithelial (<0) versus mesenchymal (>0) features (8) . The majority of metastatic tumors (who have poor overall survival) appear to be epithelial-like (EMT scores < 0, Fig. 1A, top) . Notably, in the PC1 versus EMT plot, tumors from metastatic patients or stage IV primaries (with synchronous metastasis; open and filled red cycles) appeared to cluster above the blue regression line (Stage I-III primary tumors), suggesting that metastatic tumors were more associated with PC1 than EMT.
Consistent with this figure, survival analysis using the univariate Cox proportional hazard regression model for overall survival (OS) on Moffitt468 indicates that the PC1 score was predictive of OS [HR, 1.40; 95% confidence interval (CI), 1.18-1.66, P ¼ 0.0001], while the EMT score fell short of statistical significance (HR, 1.13, 95% CI, 0.96-1.34, P ¼ 0.14). Interestingly, when the scores were used in a multivariable Cox survival model, the coefficients (logarithms of the HR) for PC1 and EMT were both highly significant, but of roughly equal magnitude and opposite numeric sign [i.e., for PC1, HR, 3.75 (worse survival); 95% CI, 2.51-5.61, P < 0.0001; for EMT, HR, 0.36 (better survival); 95% CI, 0.24-0.53, P < 0.0001, with log HRs ¼ 1.32 and -1.02]. The statistical interpretation of this result is that survival is best explained not by PC1 or EMT alone but by a score obtained by combining them into a new score to which the PC1 score contributes positively and the EMT score negatively, with roughly equal magnitudes. Thus, we elected to subtract the EMT score from the PC1 score to produce a "difference" score (DPC1.EMT). Subsequent univariate OS analysis indeed demonstrated that DPC1.EMT (HR, 1.82; 95% CI, 1.51-2.18, P < 0.0001) clearly outperformed not only EMT, but also PC1, which is supported by a significantly stronger association with metastatic tumors (Fig. 1A , middle and bottom). The DPC1.EMT score had a good association with EMT (Pearson R ¼ 0.38, P < 0.0001), but displayed an even stronger correlation with PC1 (Pearson R ¼ 0.74, P < 0.0001), suggesting that PC1 includes a non-EMT biologic component (presuming that the EMT score captures the EMT component fairly completely). In support of this notion, higher DPC1.EMT scores better separate the metastatic and nonmetastatic tumor tissues, most of which have EMT score < 0 indicating epithelial-like tumors (Fig. 1A , bottom, highlighted by red box). Moreover, it was clear that PC1, and especially DPC1.EMT, outperformed EMT in progressively deciphering the degree of tumor progression of primary colorectal cancers (from increasing primary stage to metastatic lesions (Fig. 1B) .
Furthermore, the Kaplan-Meier survival analysis shows that a higher DPC1.EMT score could better predict poorer OS for all patients (log-rank trend, P < 0.0001, Fig. 2A , left) than PC1 (log-rank trend, P ¼ 0.0006) and EMT (log-rank trend, P ¼ 0.1571; Supplementary Figs. S1A and S2A). Notably, DPC1. DPC1.EMT is associated with poor overall survival on the Moffitt468 colorectal cancer dataset and on independent colorectal cancer datasets. A, Kaplan-Meier survival analysis of quartile scores on Moffitt468 shows that a higher DPC1.EMT predicted poorer OS for all 468 patients (left), and also when limited to the 306 stage I-III primary tumors (right). Also see Supplementary Figs . S1-S3 for additional analyses on MSS, MSI, and metastatic tumors as well as for PC1 and EMT scores. B, forest plot summary of OS and RFS univariate analyses of EMT, PC1, and DPC1. EMT scores on PETACC3, LNCC, GSE14333, GEO41258, and ALMAC datasets. See Supplementary Table S4 for detailed information with other clinicopathologic and molecular variables. Note, signature scores were standardized by IQR. C, forest plot summary of RFS multivariable analyses of the DPC1.EMT score on PETACC3, LNCC, GSE14333, GEO41258, and ALMAC datasets. Note, the solid lines represent 95% CI and signature scores were standardized by IQR. See Supplementary Fig. S4 for OS multivariable analyses. Also see Supplementary Tables  S5-S9 for detailed information for PC1 and EMT scores as well as other clinicopathologic and molecular variables.
EMT predicted poorer OS for MSS (P < 0.0001) and tended toward statistical significance for MSI (P ¼ 0.085) patients (Supplementary Fig. S3A ). Moreover, when limited to the 306 stage I-III primary tumors, DPC1.EMT clearly outperformed its parental scores (P ¼ 0.0005 for DPC1.EMT, Fig.  2A , right, as compared with P ¼ 0.1437 for PC1 and P ¼ 0.3313 for EMT, Supplementary Figs. S1B and S2B ). In contrast, for metastatic tumors, like its parental scores (Supplementary Figs. S1C and S2C), DPC1.EMT did not predict poorer OS (Supplementary Fig. S3B ).
Validation of DPC1.EMT's prognostic value
The prognostic value of DPC1.EMT was also tested and confirmed by a univariate Cox regression analysis in a (Table 1C) , the HR for PC1 was 3.22 while the HR for EMT was 0.37 (coefficients 1.17 and -0.99). The statistical meaning is that also in this cohort a contrast of these two scores is significantly better than either of them alone, and quantitatively similarly as in the Moffitt data the simple difference (coefficients þ1 and À1) is close to the optimally fitting combination. The validation was then expanded to include additional independent datasets (n ¼ 1,401 colorectal cancer tumors from the other 4 datasets; Supplementary Table S2) along with various clinicopathologic and molecular variables, including age, T and N stages, number of examined lymph nodes, tumor site (left and right), MSI status, BRAF mutation, BRAF score, and/or KRAS mutation. Generally, in univariate models, DPC1. EMT outperformed PC1, which performed better than EMT (this ordering held in 11 of 15 models; Fig. 2B ; Supplementary  Table S4) .
Furthermore, the independent prognostic value of DPC1.EMT was confirmed in 3 of 5 datasets when analyzed in multivariate models including other clinicopathologic and molecular parameters, such as MSI, BRAF, and/or KRAS mutations ( Fig. 2C;  Supplementary Fig. S4 ; Supplementary Table S5 ). The signature performance was further verified by additional analyses, as shown by the survival versus score curves ( Supplementary Figs. S5 and S6) as well as the observed versus predicted survival probability curves ( Supplementary Figs. S7 and S8 ).
In addition, in agreement with the univariate results, overall, DPC1.EMT significantly outperformed both EMT and PC1 scores in multivariate OS and RFS analyses when they were compared with each other by individually (Table 1D, Supplementary Tables  S5 (DPC1.EMT It is noteworthy that currently only few colorectal cancer datasets exist and are accessible where survival and expression profiles having >100 patients. For example, GEO41258 is our smallest dataset in which we could not also find correlation with survival, neither in univariate nor in multivariate models, for wellknown variables such as MSI status, tumor side, T-stage, and stage. This may suggest that this population is not representative of colorectal cancer patients. However, we decided to include it for an unbiased report of our results.
DPC1.EMT identified metastatic tumors with non-EMT features
To explore the molecular basis for the observed prognostic improvement of DPC1.EMT from its parent PC1 and EMT scores, we examined quartile trends of these three scores versus the number of tumors harboring observed mutations of several known "driver" genes on Moffitt468, as this may provide insights into the mechanisms underlying the signature. The DPC1.EMT score had stronger trends (relative to PC1 and EMT) with tumors harboring APC-truncated mutations (negative) and BRAF (V600E) mutations (positive), as well as tumors identified as MSI-H (positive) or stage IV (positive; Fig. 3A ; for stage I-III patients, see Supplementary Fig. S9) . Notably, while percentage of distant metastatic tumors overall increased across the quartiles for all three scores, for some subgroups of combined mutations (KRAS and TP53 or BRAF and TP53), as well as in MSI-H and stage I cases, the positive trend was more pronounced for DPC1. EMT in contrast to the negative trend for EMT (Fig. 3B) , further supporting the notion that DPC1.EMT might be measuring non-EMT components of metastasis.
The DPC1.EMT score was found to be associated with several clinicopathologic and molecular variables using the The Cancer Genome Atlas (TCGA) dataset (ref. 15; Supplementary Fig. S10) , with BRAF mutation, MSI status, and mucinous tumors showing the strongest positive associations (P < 0.001). It is noteworthy that for the Moffitt468 data, MSI was positively correlated with DPC1.EMT, but uncorrelated with PC1 and negatively correlated with EMT (Supplementary Table S10 ).
Hierarchical clustering and contribution analyses of the signature genes
To better understand the molecular underpinnings of DPC1. EMT, gene expression clustering analysis was performed on the five datasets. Data show areas of strong overlap of PC1 and EMT genes, especially in the middle of the OS and RFS heatmaps, accounting for their high correlation, but also show isolated, nonoverlapping genes ( Supplementary Fig. S11 ), providing the potential for DPC1.EMT to improve outcome. Notably, the high correlation between these two signatures was shown in Supplementary Fig. S12 . As the contributions of VIM (a mesenchymal gene used to create the EMT signature) and other overlapped genes were effectively diminished in DPC1.EMT, we suspected that DPC1.EMT might better measure non-EMT features of colorectal cancer. An analysis of the GO Process of those nonoverlapping genes indicates that a number of the pathways were related to cell adhesion and cellular remodeling, which are frequently associated with metastasis (Supplementary Table  S11 ). To further address this issue, we analyzed respective weighted contributions of individual signature genes on the five datasets to identify the genes whose contributions changed the most from PC1 or EMT to DPC1.EMT (Fig. 3C) . DPC1.EMT was represented by more epithelial and less mesenchymal gene contributions as evidenced by the increased contribution of the epithelial marker CDH1, whereas the mesenchymal marker VIM and other EMTrelated genes including SPARC, TCF4, COL1A2, and COL3A1 decreased.
Identification of DPC1.EMT-correlated genes and pathways
To further explore the biologic implication of DPC1.EMT, we performed another association analysis and identified a list of top-ranked genes whose expression was either positively or negatively correlated with DPC1.EMT (Table 2 ) in a linear model on the five datasets plus the TCGA colorectal cancer dataset (15) . Many of the identified genes have been reported to have biological functions related to metastasis and cancer stem cell-like properties, as discussed below. Notably, 13 of 20 of them belong to PC1 and/or EMT signature genes. To interpret the biologic meaning of identified DPC1.EMT-correlated genes, we also carried out extensive GSEA and identified a variety of biologic processes correlated with DPC1.EMT, including negatively correlated mitochondrial metabolism (Supplementary Tables S12 and S13).
Comparison of DPC1.EMT with other known prognostic signatures
Finally, we compared the DPC1.EMT score with an expanded set of other known prognostic signatures on the five datasets in a univariate analysis. Results show that overall, DPC1.EMT was DPC1.EMT identified several subgroups of colorectal cancer and appeared to have propensity to measure non-EMT components of colorectal cancer. A and B, analysis of quartile trends (from low first to high fourth quartiles) of DPC1.EMT, PC1, and EMT scores on the Moffitt468 dataset (for all patients). A, The DPC1.EMT score trended well (relative to PC1 and EMT) with APC truncated mutation (downward) and BRAF V600E (upward), and with tumors identified as MSI-H (upward) and stage IV (upward). See Supplementary Fig. S9 for stage I-III patients. B, in the subgroups of combined mutations (KRAS and TP53 or BRAF and TP53) as well as in MSI-H and stage I cases, DPC1.EMT and EMT trended in opposite directions with respect to the number of patients with distant metastases (d_meta). C, weighted analysis of individual genes contributing to PC1 and EMT versus DPC1.EMT signatures on five datasets (PETACC3, ALMAC, LNCC, GEO41258, and GSE14333) suggests that DPC1.EMT was represented by more non-EMT components when compared with the other two scores. The genes that were the most changed from EMT or PC1 to DPC1.EMT are highlighted.
among the best prognostic signature scores for OS and RFS analyses when compared with 10 other known prognostic signatures across eight comparisons, with a higher HR more often than all other scores except DCN, with which it was tied (Fig. 4) . It is of interest to mention that DPC1.EMT showed a partial correlation with the OncotypeDX colon signature (GH) which had exploited cell proliferation as a potential prognostic marker (ref. 19 ; Supplementary Table S14) .
Discussion
Here we present the first evidence using human tissues revealing that although EMT is a dominant molecular program of colorectal cancer (8) , the non-EMT features captured by DPC1. EMT appear to be necessary to optimally predict distant metastasis. In support of this notion, the DPC1.EMT score demonstrated a strong non-EMT signature propensity in predicting distant metastasis (Fig. 1) . It also displayed a refined capacity to detect non-EMT-related metastatic potential in tumors harboring subgroups of combined mutations (KRAS and TP53 or BRAF and TP53) with abnormal RAS activation as well as in MSI-H and stage I cases generally classified with a "good" prognosis (Fig. 3) . Our findings are in agreement with the recent notion that the epithelial phenotype may be critical for the successful seeding and propagation of cancer cells at distant sites (4, (24) (25) (26) (27) (28) (29) . For instance, from a clinicopathologic point of view, cohesive epithelial migration was often observed as the predominant pattern in colorectal cancer (30) , although the related biology is not clear yet.
The result of analyzing contributions of the signature genes sheds light on the molecular underpinnings of DPC1.EMT. Compared with EMT, the gene with the greatest contribution increase in DPC1.EMT was CD24 (Fig. 3C) , previously reported as a metastasis-associated gene (31) , and a marker of colon cancer stem cells (CSC) whose properties are thought to contribute to "metastatic traits" and therapeutic resistance (5, 32) . Thus, DPC1. EMT captures both epithelial and CSC features, which are supported by a recent report demonstrating that in breast cancer, CDH1 and CD24 were highly enriched in the epithelial CSCs (ALDH1-positive), while their expression was downregulated in the mesenchymal CSCs (CD44 þ CD24 À ; ref. 33 ). ERBB3, a member of the EGFR family (34), was also identified as one of the genes whose contribution was increased in DPC1.EMT (Fig. 3C ). In agreement with this, we observed that DPC1.EMT, but not EMT, was associated with activation of the RAS/MAPK pathway, evidenced by its positive correlation with various RAS signature scores (Supplementary Table S10 ). Thus, we speculated that DPC1.EMT-associated poor prognosis might, in part, result from RAS/MAPK activation-mediated drug resistance (34) in epitheliallike colorectal cancer. Moreover, many of identified most strongly DPC1.EMT-correlated genes (Table 2) have been reported to relate to metastasis and/or CSCs. For instance, CD109 (the top positively correlated gene) has recently identified by proteomic analyses as a metastasis-associated protein marker (35) and was highly expressed in ALDH1-characterized epithelioid sarcoma CSCs (36) . Meanwhile, CDX1 and CDX2 (the two most negatively correlated genes) were reported as putative tumor suppressor genes whose expression was epigenetically repressed in colorectal cancer, and reduced expression of CDX1 inhibited CSC stem cell differentiation and thus promoted CSC renewal (35) . In support of this, HCT116, an epithelial, MSI colorectal cancer cell line that lacks expression of CDX1 was recently classified as a colon CSC cell line (2) . In addition, reduced expression of EPHB2 was associated with metastasis (37) while its overexpression induced EMT (38) , whereas the cell-cycle gene MYB, when ectopically expressed, contributed to cell migration and invasion but to also prevent metastasis (39) . Thus, identification of EPHB2 and MYB as strong negatively correlated genes of DPC1.EMT further supports the notion of non-EMT contributions to metastasis. In agreement with this, the DPC1.EMT-correlated GH prognostic signature was negatively correlated with cell-cycle genes such as MYBL2 (19) , although how GH may be potentially related to metastasis is unknown.
In further support of the negative association of DPC1.EMT with cell proliferation, pathway analyses show that DPC1.EMT was clearly correlated with negative regulation of mitochondrial metabolism (Supplementary Tables S12 and S13 ). It is noteworthy that the metastasis suppressor gene KISS1 was recently reported to promote normal mitochondrial metabolism, an anti-metastasis mechanism (40) . Moreover, it has recently been reported that the mitochondrial pyruvate carrier (MPC) played a repressor role in the Warburg effect in colorectal cancer and results indicated that inhibition of mitochondrial metabolism was connected to the maintenance and fate of cancer stem cells (41) .
In the "cell cooperativity" model (27) , Tsuji and colleagues demonstrated that primary tumors were heterogeneous and contained both mesenchymal and epithelial cell types (with mesenchymal cells populating the invasive front), but metastatic tumors contained only the cells originating from the epithelial type. This model postulates that the canonical epithelial-to-mesenchymal transition (EMT) does not fully explain metastatic potential, and should have strong epithelial features. Accordingly, the DPC1.EMT score reported here captures predominantly non-EMT features. Although DPC1.EMT is certainly distinct from EMT, it still retains some correlation with it (Supplementary Table S10 and Supplementary Fig. S12 ). Indeed, DPC1.EMT was positively correlated with the EMTrelated pathways associated with response to wounding, cell motility, extracellular matrix remodeling, activation of TGFb signaling, and angiogenesis (Supplementary Tables S12 and  S13) , as well as three important EMT-related pathways centered around SLUG1 (Supplementary Table S11 ). It is noteworthy that SLUG1 was reported to cooperate with SOX9 to convert differentiated mammary epithelial cells to stem cells (42) and stromal gene expression (EMT-related) was also recently reported to define poor prognosis subtypes in colorectal cancer (43, 44) . The reason for a significant EMT correlation for DPC1. EMT is not yet clear. According to the recent notion of epithelial plasticity (25), EMT is not a "black and white" program in human cancers, and there likely exist a variety of "gray" EMT states in most tumors especially colorectal cancer, which may be a part of the intrinsic heterogeneous nature of the disease. PC1 and EMT scores, which have quite different lists of signature genes, may differ in their abilities to measure the degree of "gray." Thus, the "EMT" components might be only partially canceled out by subtracting the EMT score from the PC1 score, resulting in the significant "residual" correlation between DPC1.EMT and EMT.
The results of this study are compelling and suggest that DPC1.EMT may be strongly predictive of adverse outcomes (metastasis and diminished survival), which should help determine which patients may need adjuvant chemotherapy in stage II/III disease (45) . However, few high quality datasets exist where molecular data have been collected with clinical data in patients with identified adjuvant chemotherapy history. Probably for this reason, we observed that the DPC1.EMT score was found significantly correlated with survival in the majority but not all the test sets. This also happened for 10 other known prognostic signatures when tested on the same datasets (Fig. 4); but overall, DPC1.EMT appeared to be a "best of assessed" prognostic score with an "optimized" capacity to predict metastasis. However, excluding the PETACC dataset, the analyzed cohorts were derived from retrospective collections of patients, hampering the generalization of our findings. Therefore, there is a clear need for further investigation of DPC1.EMT in a prospective clinical trial to determine its prognostic value in predicting which patients will metastasize and thus possibly benefit from adjuvant chemotherapy.
In conclusion, our findings suggest that poor RFS and OS can be predicted by a robust gene expression signature, DPC1.EMT, preferentially based on non-EMT stem cell biology. DPC1.EMT had a refined capacity to detect poorer overall, and in various subgroups of colorectal cancer using preferentially non-EMT features (including epithelial cancer stem cell-related properties), thereby potentially providing new targets for therapy of distant disease. The score may have utility in identifying stage II and III patients with high risk of metastasis. Thus, we believe that there should be considerable enthusiasm about further examination of this signature in a prospective clinical trial.
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